Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 451

1.

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.

van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL.

J Am Coll Cardiol. 2013 Apr 9;61(14):1498-506. doi: 10.1016/j.jacc.2012.12.044.

2.

B-type natriuretic peptide levels in obese patients with advanced heart failure.

Horwich TB, Hamilton MA, Fonarow GC.

J Am Coll Cardiol. 2006 Jan 3;47(1):85-90. Epub 2005 Dec 15.

3.

B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.

Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani L.

J Card Fail. 2005 Sep;11(7):498-503.

PMID:
16198244
5.
6.

Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.

Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton CM, Crozier IG, Yandle TG, Doughty R, MacMahon S, Sharpe N; Christchurch Cardioendocrine Research Group; Australia-New Zealand Heart Failure Group.

J Am Coll Cardiol. 2006 Jan 3;47(1):52-60. Epub 2005 Dec 15.

7.

Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.

Hsich EM, Grau-Sepulveda MV, Hernandez AF, Eapen ZJ, Xian Y, Schwamm LH, Bhatt DL, Fonarow GC.

Am Heart J. 2013 Dec;166(6):1063-1071.e3. doi: 10.1016/j.ahj.2013.08.029. Epub 2013 Oct 22.

PMID:
24268222
8.

Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study.

Donal E, Lund LH, Oger E, Hage C, Persson H, Reynaud A, Ennezat PV, Bauer F, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C; KaRen Investigators.

Arch Cardiovasc Dis. 2014 Feb;107(2):112-21. doi: 10.1016/j.acvd.2013.11.002. Epub 2013 Dec 30.

9.

Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.

Isnard R, Pousset F, Chafirovskaïa O, Carayon A, Hulot JS, Thomas D, Komajda M.

Am Heart J. 2003 Oct;146(4):729-35.

PMID:
14564330
10.

Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.

Lok DJ, Klip IT, Voors AA, Lok SI, Bruggink-André de la Porte PW, Hillege HL, Jaarsma T, van Veldhuisen DJ, van der Meer P.

Eur J Heart Fail. 2014 Sep;16(9):958-66. doi: 10.1002/ejhf.140. Epub 2014 Jul 31.

12.

Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.

Kang SH, Park JJ, Choi DJ, Yoon CH, Oh IY, Kang SM, Yoo BS, Jeon ES, Kim JJ, Cho MC, Chae SC, Ryu KH, Oh BH; KorHF Registry.

Heart. 2015 Dec;101(23):1881-8. doi: 10.1136/heartjnl-2015-307782. Epub 2015 Aug 28.

PMID:
26319121
13.

[The clinical value of B-type natriuretic peptide in the diagnosis of left heart failure].

Zhao XY, Yang YJ, Zhang J, Dang AM, Ni XH, Huang J, Kang S, Ma WH, Zhao DY.

Zhonghua Yi Xue Za Zhi. 2006 May 9;86(17):1165-9. Chinese.

PMID:
16796855
14.

Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure.

Passino C, Maria Sironi A, Favilli B, Poletti R, Prontera C, Ripoli A, Lombardi M, Emdin M.

Int J Cardiol. 2005 Sep 15;104(1):39-45.

PMID:
16137508
15.

Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.

Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M; ADHERE Scientific Advisory Committee and Investigators.

J Am Coll Cardiol. 2007 May 15;49(19):1943-50. Epub 2007 Apr 30.

16.

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.

Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R.

J Am Coll Cardiol. 2008 Jul 22;52(4):266-72. doi: 10.1016/j.jacc.2008.03.050.

17.

How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.

Maisel AS, Shah KS, Barnard D, Jaski B, Frivold G, Marais J, Azer M, Miyamoto MI, Lombardo D, Kelsay D, Iqbal N, Taub PR, Kupfer K, Lee E, Clopton P, Zile M, Greenberg B.

J Card Fail. 2016 Apr;22(4):283-93. doi: 10.1016/j.cardfail.2015.09.014. Epub 2015 Oct 31.

PMID:
26433086
18.

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.

Am J Cardiol. 2008 Sep 15;102(6):733-7. doi: 10.1016/j.amjcard.2008.04.048. Epub 2008 Jul 9.

PMID:
18773998
19.

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.

Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R.

J Am Coll Cardiol. 2001 Aug;38(2):436-42.

20.

N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).

Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators.

Eur J Heart Fail. 2013 Oct;15(10):1148-56. doi: 10.1093/eurjhf/hft076. Epub 2013 May 8.

Supplemental Content

Support Center